Trevi Therapeutics (TRVI) Competitors $6.90 -0.01 (-0.14%) Closing price 04:00 PM EasternExtended Trading$6.88 -0.02 (-0.29%) As of 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRVI vs. MLTX, ACAD, ALVO, TWST, AMRX, DNLI, RXRX, APLS, IBRX, and BHVNShould you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include MoonLake Immunotherapeutics (MLTX), ACADIA Pharmaceuticals (ACAD), Alvotech (ALVO), Twist Bioscience (TWST), Amneal Pharmaceuticals (AMRX), Denali Therapeutics (DNLI), Recursion Pharmaceuticals (RXRX), Apellis Pharmaceuticals (APLS), ImmunityBio (IBRX), and Biohaven (BHVN). These companies are all part of the "pharmaceutical products" industry. Trevi Therapeutics vs. MoonLake Immunotherapeutics ACADIA Pharmaceuticals Alvotech Twist Bioscience Amneal Pharmaceuticals Denali Therapeutics Recursion Pharmaceuticals Apellis Pharmaceuticals ImmunityBio Biohaven Trevi Therapeutics (NASDAQ:TRVI) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment. Does the MarketBeat Community prefer TRVI or MLTX? Trevi Therapeutics received 37 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 82.14% of users gave MoonLake Immunotherapeutics an outperform vote while only 67.95% of users gave Trevi Therapeutics an outperform vote. CompanyUnderperformOutperformTrevi TherapeuticsOutperform Votes10667.95% Underperform Votes5032.05% MoonLake ImmunotherapeuticsOutperform Votes6982.14% Underperform Votes1517.86% Which has more volatility and risk, TRVI or MLTX? Trevi Therapeutics has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Is TRVI or MLTX more profitable? MoonLake Immunotherapeutics' return on equity of -15.54% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Trevi TherapeuticsN/A -63.31% -57.06% MoonLake Immunotherapeutics N/A -15.54%-15.09% Which has better earnings & valuation, TRVI or MLTX? MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevi TherapeuticsN/AN/A-$29.07M-$0.47-15.01MoonLake ImmunotherapeuticsN/AN/A-$36.01M-$1.89-21.87 Do institutionals and insiders hold more shares of TRVI or MLTX? 95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 93.8% of MoonLake Immunotherapeutics shares are owned by institutional investors. 24.4% of Trevi Therapeutics shares are owned by insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor TRVI or MLTX? In the previous week, MoonLake Immunotherapeutics had 12 more articles in the media than Trevi Therapeutics. MarketBeat recorded 17 mentions for MoonLake Immunotherapeutics and 5 mentions for Trevi Therapeutics. Trevi Therapeutics' average media sentiment score of 1.37 beat MoonLake Immunotherapeutics' score of 0.76 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 5 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate TRVI or MLTX? Trevi Therapeutics currently has a consensus price target of $17.56, suggesting a potential upside of 148.90%. MoonLake Immunotherapeutics has a consensus price target of $80.50, suggesting a potential upside of 94.73%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Trevi Therapeutics is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.30MoonLake Immunotherapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryTrevi Therapeutics beats MoonLake Immunotherapeutics on 11 of the 16 factors compared between the two stocks. Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVI vs. The Competition Export to ExcelMetricTrevi TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$663.24M$6.75B$5.51B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-15.597.3222.5518.49Price / SalesN/A239.19394.97102.66Price / CashN/A65.8538.1834.62Price / Book5.476.436.694.25Net Income-$29.07M$143.21M$3.22B$248.31M7 Day Performance11.12%1.24%1.11%1.12%1 Month Performance17.40%6.09%3.59%3.68%1 Year Performance146.71%-3.34%15.65%5.19% Trevi Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVITrevi Therapeutics3.5998 of 5 stars$6.90-0.1%$17.56+154.5%+135.8%$667.11MN/A-15.6820Upcoming EarningsNews CoveragePositive NewsMLTXMoonLake Immunotherapeutics1.5486 of 5 stars$39.15-0.7%$80.50+105.6%+2.9%$2.51BN/A-30.352Upcoming EarningsAnalyst ForecastNews CoverageACADACADIA Pharmaceuticals4.2524 of 5 stars$14.66-0.5%$23.93+63.3%-12.6%$2.45B$957.80M18.80510Upcoming EarningsAnalyst ForecastALVOAlvotech1.7336 of 5 stars$8.11+2.1%$18.00+121.9%-45.9%$2.45B$489.68M-4.384Short Interest ↑TWSTTwist Bioscience3.619 of 5 stars$39.90-0.5%$52.80+32.3%+22.7%$2.38B$330.19M-11.80990Upcoming EarningsPositive NewsAMRXAmneal Pharmaceuticals3.3489 of 5 stars$7.62+1.9%$10.80+41.7%+26.6%$2.36B$2.79B-11.217,600News CoveragePositive NewsDNLIDenali Therapeutics4.1611 of 5 stars$16.25+3.6%$37.57+131.2%+7.8%$2.36B$330.53M-5.89430Upcoming EarningsPositive NewsRXRXRecursion Pharmaceuticals2.2166 of 5 stars$5.84+1.9%$8.20+40.4%-28.5%$2.35B$58.49M-3.82400Upcoming EarningsAPLSApellis Pharmaceuticals4.1113 of 5 stars$17.96+2.7%$45.35+152.5%-56.5%$2.25B$781.37M-8.85770Upcoming EarningsAnalyst ForecastAnalyst RevisionNews CoverageIBRXImmunityBio1.636 of 5 stars$2.63+0.8%$12.19+363.4%-68.6%$2.24B$14.75M-2.86590Upcoming EarningsAnalyst ForecastBHVNBiohaven3.6198 of 5 stars$21.76+9.7%$62.54+187.4%-43.0%$2.22BN/A-2.33239Upcoming EarningsAnalyst ForecastHigh Trading Volume Related Companies and Tools Related Companies MLTX Alternatives ACAD Alternatives ALVO Alternatives TWST Alternatives AMRX Alternatives DNLI Alternatives RXRX Alternatives APLS Alternatives IBRX Alternatives BHVN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRVI) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRVI Stock Free TRVI Stock Alerts